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Abstract
Background: Mortality from invasive meningococcal disease (IMD) has remained stable over the
last thirty years and it is unclear whether pre-hospital antibiotherapy actually produces a decrease
in this mortality. Our aim was to examine whether pre-hospital oral antibiotherapy reduces
mortality from IMD, adjusting for indication bias.
Methods: A retrospective analysis was made of clinical reports of all patients (n = 848) diagnosed
with IMD from 1995 to 2000 in Andalusia and the Canary Islands, Spain, and of the relationship
between the use of pre-hospital oral antibiotherapy and mortality. Indication bias was controlled
for by the propensity score technique, and a multivariate analysis was performed to determine the
probability of each patient receiving antibiotics, according to the symptoms identified before
admission. Data on in-hospital death, use of antibiotics and demographic variables were collected.
A logistic regression analysis was then carried out, using death as the dependent variable, and pre-
hospital antibiotic use, age, time from onset of symptoms to parenteral antibiotics and the
propensity score as independent variables.
Results: Data were recorded on 848 patients, 49 (5.72%) of whom died. Of the total number of
patients, 226 had received oral antibiotics before admission, mainly betalactams during the previous
48 hours. After adjusting the association between the use of antibiotics and death for age, time
between onset of symptoms and in-hospital antibiotic treatment, pre-hospital oral antibiotherapy
remained a significant protective factor (Odds Ratio for death 0.37, 95% confidence interval 0.15–
0.93).
Conclusion: Pre-hospital oral antibiotherapy appears to reduce IMD mortality.
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Background
Invasive Meningococcal Disease (IMD) remains an impor-
tant cause of morbidity and mortality worldwide [1].
Although in-hospital antibiotic use and intensive care sup-
port have become more widespread, the mortality associ-
ated with IMD has remained stable over the last thirty years
[2]. Pre-hospital antibiotic therapy has been recommended
to lower the incidence of IMD-associated mortality [3,4],
but an important controversy remains. A recent systematic
review of the literature showed that indication bias was
present in all the studies published, and therefore no defin-
itive advice could be given concerning this medication [5].
Indication bias was present in outpatients receiving
parenteral antibiotics and in those receiving oral antibio-
therapy. In the former case, the patients with a poor prog-
nosis are probably those who receive pre-hospital
parenteral antibiotics [6,7], and the benefit of the interven-
tion is hard to demonstrate. In the second group (patients
receiving pre-hospital oral antibiotics), the patients with a
better a priori prognosis are probably given oral antibiotics;
they are less likely to have experienced an explosive clinical
course and tend to present fewer alarm symptoms. In this
case, thus, antibiotics are being given to those with less
severe forms of IMD (indication bias), and so the actual
effect of the intervention cannot be postulated.
A randomised, clinical trial to clarify the repercussion of
the use of oral antibiotics within the context of IMD is dif-
ficult to design, as the disease generally requires a very
high index of clinical suspicion to be diagnosed at the
onset of the process.
In this study we attempted to analyse the effect of pre-hos-
pital oral antibiotics, while controlling for indication bias
through a statistical technique called the propensity score
method. Propensity score was proposed in 1983 as a tech-
nique to control the a priori probability of receiving one or
another treatment [8], attempting to equate it with ran-
domisation in circumstances where this is not possible. In
this study, the propensity score was used to assign each
patient the possibility of pre-hospital oral antibiotherapy
in accordance with symptoms registered before hospital
admission, thereby seeking to relate the likelihood of
receiving this treatment to the symptoms recorded in the
clinical history – these being the reason for the antibio-
therapy. Recording the objective data found on examina-
tion, for all the patients from the onset of symptoms, is
not possible. However, it is feasible to identify the symp-
toms recorded in a clinical history and to determine the
possible association of any symptom or symptoms with a
better or worse prognosis of IMD.
Methods
Design
A retrospective follow-up study was conducted from week
40 in 1995 to week 41 in 2000 at 31 hospitals in Andalu-
sia and the Canary Islands (Spain). The study was
approved by the Ethics and Research Committee of the
Costa del Sol Hospital (Marbella, Spain).
Patients
All cases of IMD, coded as such on patient discharge
reports in the diagnostic registries at each hospital, were
collected during the study period. Eligible patients were
all those diagnosed with IMD and aged one year or older.
The diagnosis was interpreted as definite if there was a
microbiological culture of Neisseria meningitidis from a
sterile sample, probable if this condition was not fulfilled
but there was a Gram stain compatible with Neisseria men-
ingitidis, and possible if neither of these two conditions
were fulfilled but the diagnosis was based on clinical sus-
picion.
Variables and Measurements
The following variables were recorded: demographic data
(sex, age); number of contacts with Health Services at
which the patient presented similar symptoms to those
leading to hospital admission; symptoms prior to admis-
sion; physical signs on admission to the emergency
department, including axilar temperature, heart rate and
systolic blood pressure; use of oral antibiotics during the
two weeks before admission; time from onset of symp-
toms to administration of parenteral betalactams; and sta-
tus at discharge. Microbiological data collected included
the results of blood cultures and/or cerebrospinal fluid
(CSF) and a Gram stain.
Statistical Analysis
We estimated that at least 1,103 patients would be needed
for the study to achieve 80% power to detect an odds ratio
(OR) of 2, assuming a 30% prevalence of out-patient anti-
biotic use, a mortality rate of 5% in persons not using
antibiotics and a two-sided α of 5%. The primary end
point was mortality during hospital stay. The mean and
95% confidence interval (CI) were calculated for the
quantitative variables, and percentages were calculated for
the qualitative variables. A univariate analysis was per-
formed for the result variable "death", to estimate the OR
and the corresponding 95% CI.
The propensity score was defined as the probability of
receiving pre-hospital oral antibiotics according to the
symptoms present prior to admission. The symptoms
were selected in accordance with the natural progression
of IMD and, thus, with the decision to prescribe antibiot-
ics or not. To estimate this probability, an initial logistic
regression analysis was performed with all the symptoms
as independent variables and the use of antibiotherapy
(yes/no) as the dependent variable, using P < 0.05 as the
inclusion criterion for independent variables. Further
logistic regression analysis was then performed with the
propensity score, out-patient oral antibiotics, time fromBMC Public Health 2009, 9:95 http://www.biomedcentral.com/1471-2458/9/95
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onset of symptoms to parenteral antibiotics and age as
independent variables and mortality as the dependent
variable. The pre-hospital use of antibiotherapy and the
variable propensity score were obligatory components in
the model, with the other variables being included if they
fulfilled the statistical criterion (P < 0.05). This analysis
was then repeated excluding clinical suspicions. For all
these analyses, SPSS 10.0 statistical software was used.
After calculating the propensity score for the patients, each
of those who had received extra-hospital antibiotherapy
was matched with a control who had not – specifically,
with the patient presenting the closest propensity score –
using R 2.4.1 statistical software. This 1:1 pairing gave rise
to a loss of patients who had not been exposed to extra-
hospital antibiotherapy. From these two groups of
patients, balanced as regards their possibility of receiving
extra-hospital antibiotherapy, we compared the propor-
tion of deaths, again using the χ2 test or Fisher's exact test
when appropriate, thus generating a new OR with its cor-
responding 95% CI.
Results
Description of the cohort and univariate association with 
death
A total of 848 patients were studied, 49 (5.72%) of whom
died. The mean age of the cohort, 449 (52.9%) of whom
were male, was 10.4 years (95% CI, 9.4–11.3). The older
the patient, the greater the mortality, with 4.9% deaths in
patients aged under 11 years vs. 25% deaths in those over
65 years.
The number of health service contacts prior to admission
was zero in 502 patients (59.2%) and one in 269 (31.7%).
No difference in mortality was observed depending on the
number of health service contacts. No deaths occurred
among those who had three or more contacts prior to
admission.
Table 1 shows the symptoms recorded in the clinical his-
tory, with the corresponding OR exploring the association
with mortality. The most frequent symptom was fever,
while convulsions were the first symptom to appear on
admission. More specific symptoms of IMD, such as
petechiae, occurred in just over half the patients, and had
a mean duration of eight hours before admission. The
presence of convulsions and cold-like symptoms was sig-
nificantly associated with higher mortality, whereas the
presence of nausea/vomiting was a protective factor. The
physical signs and symptoms on admission to hospital are
shown in Table 2. Again, the most frequent symptom was
fever, followed by petechiae.
The mean axilar temperature, measured in the emergency
room in 678 patients (80%), was 38.2°C (95% CI, 38.2–
38.3). The average heart rate, measured in 519 patients
(61.2%), was 128 beats per minute (95% CI, 125–130)
and the mean systolic blood pressure, measured in 572
patients (67.5%), was 102.6 mmHg (95% CI, 100.8–
104.5). An axilar temperature ≥40°C, a heart rate ≤60
bpm or a systolic blood pressure ≤80 mmHg were associ-
ated with higher mortality (OR for each: 4, 95% CI, 1.1–
14.3; 20.7, 95% CI, 4.4–96.5; and 2.7, 95% CI, 1.3–5.6,
respectively). Of the cases examined, 75.5% were definite,
4.6% were probable and 19.9% were possible.
Of the entire cohort, 226 patients (26.7%) received pre-
hospital antibiotics. The main characteristics of the
patients, grouped according to whether they had received
pre-hospital antibiotics or not, are shown in Table 3. The
mortality among the patients who had taken antibiotics
was 2.7% vs. 6.9% among those who had not (OR: 0.37,
95% CI: 0.15–0.88). The main group of antibiotics used
was betalactams (181 patients), followed by macrolides
(36 patients). The vast majority of patients (92.2%) had
begun antibiotics during the 48 hours prior to hospital
admission. The main point of indication for antibiotic
therapy was the primary care physician (48.2%), followed
by hospital doctors (26.8%). 10.5% of the patients who
took antibiotics had self-medicated. The mean time from
the first symptoms to the first dose of parenteral antibiotic
in the hospital was 29.7 h. No difference was observed in
the time from the first symptoms to the first dose of
Table 1: Symptoms recorded on clinical history, with OR for death (univariate analysis).
Symptom N (%) Mean duration in hours (95% CI) OR (95% CI)
Fever 814 (96) 22 (21–23) 0.44 (0.14–1.30)
Nausea/Vomiting 647 (76.3) 18 (16–19) 0.47 (0.26–0.85)
Petechiae 432 (50.9) 8 (6–9) 0.77 (0.43–1.38)
Headache 338 (39.9) 23 (21–26) 0.72 (0.39–1.33)
Low level of consciousness 334 (39.4) 15 (13–17) 0.60 (0.31–1.13)
Cold-like symptoms 127 (15) 60 (48–72) 2.43 (1.27–4.66)
Pharyngoamygdalitis 119 (14) 35 (29–41) 1.2 (0.55–2.65)
Arthralgia 113 (13.3) 20 (16–25) 1.29 (0.58–2.83)
Neck stiffness 71 (8.4) 16 (10–22) 0.45 (0.11–1.89)
Irritability 50 (5.9) 14 (11–18) 0.32 (0.04–2.36)
Convulsions 37 (4.4) 3 (1–4) 2.72 (1.01–7.33)BMC Public Health 2009, 9:95 http://www.biomedcentral.com/1471-2458/9/95
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parenteral antibiotic between those who had taken antibi-
otics prior to arrival at the hospital and those who had
not.
A total of 323 patients (38.1%) had sepsis, 336 (39.6%)
meningitis and the rest a mixed clinical form, with mor-
tality rates of 10.7%, 2.1% and 4.2%, respectively (P <
0.001). Sepsis vs. the other clinical forms had an OR for
death of 4 (2.2–7.6).
Logistic regression analysis
The regression model used to estimate the probability of
the indication for pre-hospital antibiotic use included all
of the symptoms listed in Table 1. Logistic regression anal-
ysis was performed to control the association between
pre-hospital antibiotherapy and in-hospital mortality,
adjusting for propensity score, time from first symptoms
to first dose of parenteral antibiotic in hospital and age.
The clinical forms variable was excluded because it pre-
sented colinearity with symptoms. In this analysis, only
age and the use of antibiotics were significantly associated
with death. The OR for age was 1.03 (95% CI, 1.01–1.04)
and for the use of antibiotics 0.37 (95% CI, 0.15–0.93)
(Table 4). No other variable had a significant association.
Thus, the OR for death in patients who did not take anti-
biotics was 2.7 (95% CI, 1.07–6.66) and the number
needed to treat (NNT) to avoid a death was 23.5 (95% CI,
14–73.2).
When the logistic regression analysis was performed with
the cohort, and clinical suspicions were excluded, age con-
tinued to present a significant association with death (OR
1.03; 95% CI, 1.01–1.05) but this was not so for the use
of antibiotics (OR 0.4; 95% CI, 0.11–1.4).
A further analysis was then performed. Cases of patients
who had received pre-hospital antibiotic treatment were
matched with those of other patients who had not, using
the closest propensity score value to determine this
matching. Tables 5 shows the effects of this matching, on
baseline age values, symptoms and time from onset of
first symptoms to first in-hospital dose of parenteral anti-
biotics. A sub-analysis of 436 patients (218 in each arm)
was then performed to examine the association between
pre-hospital antibiotic use and death, producing an OR of
0.41 (95% CI, 0.13–1.17) for antibiotic use.
Discussion
The use of oral antibiotherapy prior to hospital admission
has resulted in significant benefits in terms of reduced
mortality. It is evident that the use of antibiotics dimin-
ishes the mass of Neisseria meningitidis, and that the pro-
duction of cytokines and endotoxins is generally lower in
patients taking pre-hospital antibiotics [9]. Previous stud-
ies have shown that the use of pre-hospital antibiotics is
Table 2: Physical signs on the initial examination at admission to 
the emergency room, with OR for death (univariate analysis).
Physical sign N (%) OR (95% CI)
Fever 621 (73.2) 0.82 (0.44–1.53)
Petechiae 562 (66.3) 0.72 (0.40–1.30)
Kernig/Brudszinky signs 405 (47.8) 0.68 (0.37–1.22)
Nausea/Vomiting 282 (33.3) 0.64 (0.33–1.24)
Pharyngoamygdalitis 259 (30.5) 0.3 (0.13–0.71)
Low level of consciousness 234 (27.6) 1.89 (1.04–3.4)
Cyanosis 117 (13.8) 2.41 (1.24–4.7)
Irritability 110 (13) 0.93 (0.39–2.24)
Cold-like symptoms 75 (8.8) 0.66 (0.20–2.17)
Arthritis-arthralgia 61 (7.2) 0.53 (0.12–2.25)
Convulsions 20 (2.4) 4.35 (1.40–13.55)
Table 3: Characteristics of patients according to whether they received pre-hospital antibiotic treatment or not.
Variable Pre-hospital antibiotic use No pre-hospital antibiotic use
Gender (% male) 50.4 53.8
Age, mean (years) 9.6 10.2
Fever 95.6 96.1
Nausea/Vomiting 82.3 74.1
Petechiae 46.5 52.6
Headache 45.6 37.8
Low level of consciousness 39.8 39.2
Cold-like symptoms 16.8 14.3
Pharyngoamygdalitis 30.5 8
Arthralgia 11.9 13.8
Neck stiffness 13.3 6.6
Irritability 3.1 6.9
Convulsions 3.5 4.7
Time first symptoms to in-hospital antibiotics, mean (hours) 38.5 26.6
Definite cases 77.9 89.1
Categoric variables, such as symptoms, are given in percentagesBMC Public Health 2009, 9:95 http://www.biomedcentral.com/1471-2458/9/95
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associated with less culture positivity (supporting the
hypothesis of a greater reduction in bacterial mass) and a
lower rate of clinical complications [10].
Our study began before the large-scale vaccination of chil-
dren against Nesseria meningitidis but the effect of antibi-
otics later on in life is very probably the same now,
because the protection acquired is independent of sero-
group. On the other hand, mortality during outbreaks is
greater than during an endemic situation [11]. Spain was
suffering an outbreak when cases for this study were being
collected. We cannot therefore affirm that the use of pre-
hospital oral antibiotherapy is beneficial in non-outbreak
conditions. No patient presented evidence of pre-hospital
parenteral antibiotic use, and so oral use alone (collected
in the clinical report in all cases) was assumed.
An important group of patients not included in this study
is constituted of those diagnosed with IMD and who died
before hospital admission. This, obviously, is a special
group and we cannot assess the efficacy of their treatment.
Another possible source of confusion concerns the
patients with suspected IMD, as symptoms could pertain
to diseases other than IMD. However, the logistic regres-
sion results for the entire cohort and for the cohort exclud-
ing these patients were similar. Another limitation of our
study is that memory bias may be present in the clinical
report: the family or the patients may not have recalled all
the symptoms or whether pre-hospital antibiotics were
taken. However, this bias is compensated for by the fact
that the cases were collected during a time of great fear of
IMD in Spain, with an important diffusion of information
in the mass media.
To date, only five cohort studies have been published
exploring the relationship between the use of oral antibi-
otics and mortality for IMD [7,12-15]. Except for the
cohort analysed by Barquet et al., no other study has con-
trolled for the relationship between use of antibiotics and
death for any covariable. Although all the studies found
benefits to be gained from oral antibiotics, some authors,
such as Morant, advise against their use, on the grounds
that this treatment reduces the possibility of obtaining an
accurate microbiological diagnosis and that the benefit in
terms of survival is not significant. Indication bias can be
observed in the work of García et al., in which all the
patients who received oral antibiotherapy presented men-
ingitis as a clinical form on admission to hospital. Only
the study by Barquet et al. found a significant association
between oral antibiotics and mortality. This association
was controlled for age, neurological focus and haemor-
rhagic diathesis. Of these groups, two could be inferred by
the use of antibiotics (neurological focus and haemor-
rhagic diathesis). In other words, pre-hospital antibiotics
could, theoretically, have influenced the appearance or
otherwise of these two symptoms; thus, the use of clinical
items present at admission to hospital is not a good way
of controlling the previous use of antibiotherapy. As the
use of antibiotics may well modify the progression and
prognosis of IMD, it is preferable to control the relation-
ship between antibiotics and mortality through a variable
that is less affected by treatment. Accordingly, we built our
propensity score using symptoms studied in the anamne-
sis. This explains why the antibiotics prescribed and the
Table 4: Results of logistic regression analysis, with death as 
dependent variable.
Variable OR 95% CI
Propensity score 0.95 0.09–9.76
Pre-hospital antibiotic use 0.37 0.15–0.93
Age 1.03 1.01–1.04
Interval symptoms to in-hospital treatment 0.99 0.98–1.01
Table 5: Mean values of the variables included in the matching process, before and after the latter was performed. 
Variable Mean value
(treated patients) before 
matching
Mean value
(non-treated patients) 
before matching
Mean value
(treated patients) after 
matching
Mean value
(non-treated patients) 
after matching
Age (years) 9.6 10.2 9.6 9.5
Fever 0.05 0.04 0.04 0.04
Nausea/Vomiting 0.54 0.62 0.54 0.55
Petechiae 0.16 0.25 0.16 0.16
Headache 0.88 0.86 0.88 0.88
Reduced LC 0.59 0.86 0.59 0.58
Cold-like symptoms 0.97 0.92 0.96 0.96
Pharyngoamygdalitis 0.83 0.86 0.83 0.80
Arthralgia 0.70 0.92 0.70 0.78
Neck stiffness 0.87 0.93 0.86 0.84
Irritability 0.96 0.95 0.96 0.95
Convulsions 0.55 0.47 0.55 0.56
STI (hours) 38.55 26.62 38.5 35.8
LC: Level of consciousness; STI: Symptom-treatment interval.BMC Public Health 2009, 9:95 http://www.biomedcentral.com/1471-2458/9/95
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mortality rate were less influential than the data deter-
mined in the emergency room. The other three studies did
not control for the effect of antibiotics on mortality
caused by IMD. The comments to the studies with oral
antibiotics were uniform, and we are unaware if treatment
was given to a group of patients who were healthier than
those not taking antibiotics, an observation that has also
been made in a recent systematic review of the literature
[5].
It is difficult to elucidate the actual value of pre-hospital
antibiotics in reducing mortality from IMD. One solution
might be to perform a randomised clinical trial. However,
IMD is a very difficult disease to diagnose prior to hospital
admission. Only a large cohort study including cases diag-
nosed at all levels of the Health Service could answer this
question. The use of statistical techniques such as the pro-
pensity score to control for indication bias could be use-
ful. Such techniques enable us to control for the known
risk factors reasonably well, but not the unknown ones;
therefore, we must be cautious in the final interpretation.
Another important concern is the relationship between
pre-hospital parenteral antibiotics and death from IMD,
which is not studied in this paper.
At a time when patients who receive in-hospital antibiot-
ics generally respond well, and when support treatment
has improved and large-scale vaccination programmes
have been implemented, the pre-hospital use of antibiot-
ics remains one of the few treatments remaining to be
implemented in order to improve survival rates among
patients with IMD, and then it may no longer be repeated
that "no infection kills so quickly" [16].
Conclusion
Pre-hospital oral antibiotherapy appears to reduce IMD
mortality, controlling indication bias.
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